Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-02-12, Stock:JNJ, The news for the past five days is as follows:
2018-02-05: NEWS1: Cramer's sell-off strategy: Have your shopping list ready.NEWS2: Here are some stocks you can buy on the dip: Technician.NEWS3: The Dow just touched correction territory: Here are the stocks that led the drop.NEWS4: Early Prostate Cancer Kept at Bay in Two Studies for High-Risk Men.NEWS5: Notable Monday Option Activity: MS, JNJ, HUN.NEWS6: Notable Monday Option Activity: MS, JNJ, HUN.NEWS7: Health-care ETF tumbles, pressured by pharmaceutical company weakness.NEWS8: Johnson & Johnson falls on report that lawsuits could expose potentially damaging documents.NEWS9: Will Tax Reform Affect Health Care Sector Earnings in 2018?.NEWS10: 3 Top Pharmaceutical Stocks to Buy Now.NEWS11: 3 Top Pharmaceutical Stocks to Buy Now.NEWS12: Bristol Myers earnings power shares in the green among a sea of red.NEWS13: Why Abbott Laboratories’ Product Pipeline Is Expected to Boost 2018.NEWS14: GlaxoSmithKline Is Global Leader in Consumer Healthcare Business.NEWS15: 3 Top Pharmaceutical Stocks to Buy Now.NEWS16: GSK Is Focused on Innovative Assets in Oncology Research Pipeline.NEWS17: Multiple Myeloma May Be Strong Growth Area for GlaxoSmithKline.
2018-02-06: NEWS1: 3 Dividend Stocks That Should Pay You the Rest of Your Life.NEWS2: Jeff Auxier Comments on Johnson & Johnson.NEWS3: Bitcoin Shows Us Why It’s Not Always About You.NEWS4: Bitcoin Shows Us Why It’s Not Always About You.NEWS5: See what the IHS Markit Score report has to say about Johnson & Johnson..NEWS6: GSK Has Emerged as Leading Player in Over-the-Counter Market.NEWS7: 3 Great Dividend Stocks to Buy in the Broad Market Rout.NEWS8: Will the Corporate Tax Cuts Lead to Bigger Share Buybacks?.NEWS9: So what happens next?.NEWS10: Asian markets feel the heat, where sell-off accelerating.
2018-02-07: NEWS1: EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Johnson & Johnson – JNJ.NEWS2: Top Defensive Consumer Stocks for 2018.NEWS3: TBPH Inks $1Bln Deal, SGMO Hits Yearly High, ANAB Is Back Again.NEWS4: TBPH Inks $1Bln Deal, SGMO Hits Yearly High, ANAB Is Back Again.NEWS5: Buying On Dips Is Good But This Time Investors Got Burned.NEWS6: Why Theravance Biopharma Shares Are Soaring.NEWS7: Johnson & Johnson to Participate in RBC Capital Markets 2018 Global Healthcare Conference.NEWS8: Humira Will Remain a Key Growth Driver for AbbVie in 2018.NEWS9: Sanofi’s $11.6 Billion Bioverativ Acquisition: Highlights.NEWS10: Implied PWV Analyst Target Price: $42.NEWS11: Implied PWV Analyst Target Price: $42.NEWS12: 3 Dividend Stocks That Should Pay You the Rest of Your Life.NEWS13: 3 Dividend Stocks That Should Pay You the Rest of Your Life.NEWS14: 5 Dow Jones Stocks to Buy That Are Huge Bargains Now.NEWS15: 5 Dow Jones Stocks to Buy That Are Huge Bargains Now.
2018-02-08: NEWS1: IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Johnson & Johnson.NEWS2: Market Correction in 2018? Hedge Funds Say You Should Own These 5 Stocks.NEWS3: Novartis' Cosentyx Label Expanded to Include Scalp Psoriasis.NEWS4: Novartis' Cosentyx Label Expanded to Include Scalp Psoriasis.NEWS5: Theravance, J&J Ink Deal for Inflammatory Intestinal Drug.NEWS6: Theravance, J&J Ink Deal for Inflammatory Intestinal Drug.NEWS7: Performance of Amgen’s Kyprolis in 2017.NEWS8: Johnson & Johnson to Participate in the 2018 CAGNY Conference.NEWS9: Theravance, J&J Ink Deal for Inflammatory Intestinal Drug.NEWS10: Novartis&apos; Cosentyx Label Expanded to Include Scalp Psoriasis.NEWS11: Venclexta May Prove a Novel Chemotherapy-Free Treatment Option.NEWS12: SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Johnson & Johnson (JNJ).NEWS13: The Alzheimer's Drug Pipeline: High Failure Rates In Research On An Increasingly Common Disease.NEWS14: Imbruvica Leads in the Chronic Lymphocytic Leukemia Space.NEWS15: Janssen and Johnson & Johnson to Provide Webcast Presentation on Phase 3 Data for Apalutamide and the Janssen Prostate Cancer Strategy and Portfolio.NEWS16: ABBV to Focus on Advancing Late-Stage Immunology Research in 2018.NEWS17: 3 Large-Cap Healthcare Stocks You Must Buy Following the Market Pullback.
2018-02-09: NEWS1: 7 Blue-Chip Stocks to Buy Amid Record Selloff.NEWS2: 7 Blue-Chip Stocks to Buy Amid Record Selloff.NEWS3: SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Johnson & Johnson.NEWS4: Solid Q4 Earnings Drive Pharma ETF Outlook.NEWS5: Solid Q4 Earnings Drive Pharma ETF Outlook.NEWS6: FDA Okays J&J's Prostate Cancer Drug in First-Line Setting.NEWS7: FDA Okays J&J's Prostate Cancer Drug in First-Line Setting.NEWS8: Glaxo's (GSK) Begins Phase III HIV Two-Drug Regimen Study.NEWS9: Glaxo's (GSK) Begins Phase III HIV Two-Drug Regimen Study.NEWS10: FDA Okays J&J&apos;s Prostate Cancer Drug in First-Line Setting.NEWS11: Rosen Law Firm Files Securities Class Action Lawsuit Against Johnson & Johnson.NEWS12: Solid Q4 Earnings Drive Pharma ETF Outlook.NEWS13: SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Johnson & Johnson (JNJ) & Lead Plaintiff Deadline: April 9, 2018.NEWS14: SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Johnson & Johnson (JNJ) & Lead Plaintiff Deadline: April 9, 2018.NEWS15: What Drove Pfizer’s 4Q17 Growth?.NEWS16: Amgen’s Neulasta and Enbrel in 4Q17 and 2017.NEWS17: 3 Dividend Stocks Perfect for Retirement.NEWS18: 3 Dividend Stocks Perfect for Retirement.NEWS19: See what the IHS Markit Score report has to say about Johnson & Johnson..NEWS20: How Did Pfizer’s Geographical Regions Perform in 4Q17?.NEWS21: 3 Dividend Stocks Perfect for Retirement.NEWS22: JNJ INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Johnson & Johnson Investors.NEWS23: FDA Nod For JNJ, CORI Awaits Results In Q2, MDGL's HeFH Data Fails To Impress.NEWS24: FDA Nod For JNJ, CORI Awaits Results In Q2, MDGL's HeFH Data Fails To Impress.

Answer: Rise